

**Announcement  
11 August 2014**

**Coloplast – transactions in connection with share buy-back programme**

As mentioned in Announcement No. 2/2014 Coloplast is initiating the first part of the share buy-back programme totalling up to DKK 1bn. This part of the programme of DKK500m is expected to take place from 3 March, 2014 to 31 August, 2014 at the latest. The second part of the programme, of also DKK 500m, is executed in the 2014/15 fiscal year.

The following transactions have been executed during the period 4 August – 8 August 2014:

Date	Number of shares	Average buying price	Amount DKK
4 August	7,000	468.0000	3,276,000
5 August	7,000	474.6000	3,322,200
6 August	7,000	473.8000	3,316,600
7 August	7,000	471.9000	3,303,300
8 August	7,000	465.4000	3,257,800
Accumulated until now under the programme	1,039,000	457.0051	474,828,300

Henceforth, Coloplast owns 9,433,187 own B shares of DKK 1 equal to 4.29 % of the company's total share capital.

The second part of the programme, of also DKK 500m, is expected to take place from 1 October, 2014 to 30 September, 2015.

## **For further information, please contact**

### **Investors and analysts**

Ian S.E. Christensen  
Vice President, Investor Relations  
Tel. +45 4911 1800/+45 4911 1301  
Email: dkisec@coloplast.com

Nick Fridberg  
Sr. Investor Relations Manager  
Tel. +45 4911 1800/+45 4911 1456  
Email: dknf@coloplast.com

### **Press and the media**

Simon Mehl Augustesen  
Media Relations Manager  
Tel. +45 4911 3488  
Email: dksia@coloplast.com

This announcement is available in a Danish and an English-language version.  
In the event of discrepancies, the Danish version shall prevail.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2014-08 All rights reserved Coloplast A/S, 3050 Humlebæk, Denmark.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.

Our business includes Ostomy Care, Urology Care, Continence Care and Wound and Skin Care. We operate globally and employ more than 8,500 people.